1. Introduction {#s0005}
===============

Langerhans cells (LCs) are unique antigen-presenting cells (APC) in the epidermis whose roles in host defense have become clearer over the last few years. We previously demonstrated that LCs take up protein antigens and bacterial toxins by extending their dendrites through intact tight junction barriers ([@bb0115]) to initiate protective humoral responses ([@bb0135], [@bb0145]). This non-redundant function for LCs *in vivo* was observed by controlling the distribution of antigens and utilizing protein antigens that do not penetrate epidermal tight junctions and thus are accessible to only LCs ([@bb0145]). On the other hand, when epidermal barriers are breached during epicutaneous *Candida albicans* infection, LCs are capable of inducing Th17-mediated cellular responses ([@bb0060]). The route of antigen delivery that allows for natural antigen uptake by LCs was an important factor in determining LC function in these studies.

Langerin is a C-type lectin required for the formation of Birbeck granules ([@bb0100], [@bb0205]) and was demonstrated to be an endocytic receptor in *in vitro* propagated LCs and in fibroblasts transfected with *Langerin* ([@bb0205]). However, the genomic ablation of langerin did not result in any obvious immune phenotypes ([@bb0100]), and its function(s) *in vivo* had remained elusive. Human LCs have been shown to scavenge HIV *via* langerin ([@bb0225]), but functional contributions of langerin during immune responses have not been demonstrated.

Whether LCs are capable of suppressing immunity has been a topic of debate. Loss of LCs leads to attenuated disease in leishmaniasis with decreased numbers of regulatory T (T~reg~) cells ([@bb0080]), and the treatment of mice with antigen-conjugated anti-langerin antibodies results in enhanced T~reg~ cell expansion ([@bb0030], [@bb0055]). LCs have also recently been shown to induce the expansion of T~reg~ cells in response to ionizing irradiation ([@bb0150]). However, the physiological setting in which LCs mediate immuno-regulatory responses and whether this occurs in an antigen-specific manner has yet to be clearly demonstrated.

Past models including contact hypersensitivity responses, intradermal injection of pathogens and transgenic mice expressing neo-autoantigens have been utilized to explore LC function. However, the route of antigen delivery or the superphysiological load of antigens may lead to experimental outcomes that do not reflect physiological LC function. This issue may be avoided by studying immune responses against keratinocyte-associated autoantigens that are physiologically expressed.

Desmoglein 3 (Dsg3) is a classic cadherin family cell adhesion molecule and a major desmosomal glycoprotein that is expressed by keratinocytes ([@bb0005]). Dsg3 is not only critical for maintaining epidermal integrity, it is also a *bona fide* autoantigen that is targeted in pemphigus vulgaris, an autoimmune blistering disease ([@bb0005]). While mechanisms regarding T cell immunity against Dsg3 remain incompletely characterized, a mouse model has helped provide some insight ([@bb0190]). Experimental autoimmune dermatitis (EAD) is a mouse model in which CD4^+^ T cells target Dsg3 to mediate autoimmune skin inflammation ([@bb0195]) and represents a unique model in which autoimmunity against a physiologically expressed, functional self-antigen can be studied. Herein, we utilized *in vitro* and *in vivo* systems and determined that langerin-mediated acquisition of Dsg3 by LCs leads to the expansion of antigen-specific T~reg~ cells. We also demonstrate that LCs expanded T~reg~ cells *via* a mechanism that involves direct IL-2 signaling in LCs.

2. Materials and Methods {#s0010}
========================

2.1. Mice {#s0015}
---------

C57BL/6J and C57BL/6J *Rag2*^−/−^ mice were purchased from CLEA Japan, Inc. and the Central Institute for Experimental Animals (Tokyo, Japan), respectively. Langerin-DTA mice ([@bb0065]) were crossed with the C57BL/6J *Rag2*^−/−^ background. Homozygous or heterozygous Langerin-DTR mice ([@bb0015]) in the C57BL/6SJL (CD45.1) background were obtained by breeding homozygous Langerin-DTR mice with each other or with C57BL/6SJL wild-type mice. *Dsg3*^−/−^ mice were crossed with K5-Dsg1 transgenic mice, which express another desmosomal protein, Dsg1, in keratinocytes ([@bb0045]). The Dsg1 expression driven by the K5 promoter compensates for the loss of Dsg3 and ameliorates the mucosal erosions that *Dsg3*^−/−^ mice are prone to develop, thereby enhancing the viability of *Dsg3*^−/−^ mice ([@bb0045]). For the sake of simplicity, the K5-Dsg1 transgenic *Dsg3*^−/−^ mice have been referred to as *Dsg3*^−/−^ mice throughout this manuscript. The Dsg3-specific T cell receptor transgenic mice (H1 mice) in the C57BL/6J background were previously generated ([@bb0195]). *CD25*^*−/−*^ mice were kindly provided by Tai Xuguang and Alfred Singer (National Cancer Institute, National Insitutes of Health, Bethesda).

To generate K5-Dsg3-eGFP mice, a transgene vector pGEM3Z-hK5-mDsg3-EGFP containing the human keratin 5 (K5) promoter \[which was kindly provided by Dr. Junji Takeda (Osaka University)\], a full length mouse Dsg3 (mDsg3) and enhanced GFP (eGFP) were constructed. Full length mDsg3 fused with eGFP was subcloned between the β-globin cassette and BGHpA of the modified K14pNotIpGEM3Z vector ([@bb0045]). Then, the K14 promoter was replaced with the K5 promoter as previously described ([@bb0045]). The nucleotide region from the K5 promotor to BGHpA was excised and microinjected into the pronuclei of the C57BL/6J mice zygotes. The zygotes were implanted into pseudopregnant foster C57BL/6J mice to generate mDsg3-eGFP transgenic mice.

All mice were bred and housed in specific pathogen-free facilities. All animal procedures and study protocols were approved by the Keio University Ethics Committee for Animal Experiments.

2.2. Antibodies {#s0020}
---------------

Anti-mouse langerin (clone L31, eBioscience) was used either purified or in conjugated forms labeled in house with Alexa Fluor 647 (Invitrogen). Additional anti-mouse mAbs obtained from BioLegend (except otherwise noted) were used for flow cytometry or immunofluorescence staining: CD122 (TM-β1), CD132 (TUGm2), CD25 (PC61), CD3ε (145-2C11), CD4 (GK1.5), CD45 (30F-11), CD80 (16-10A1), CD86 (GL-1), EpCAM (G8.8), Foxp3 (FJK-16s; eBioscience), IL-2 (JES6-1A12), MHC II (anti-IA/IE; M5/114.15.2), Vβ6 (RR4-7; BD Bioscience), CD11b (M1/70; eBioscience) and pSTAT5 (pY694: BD Biosciences).

LEAF™ Purified anti-mouse I-A/I-E (M5/114.15.2, BioLegend) and the appropriate isotypes were used for functional assays. Mouse CD4 MicroBeads (L3T4, Miltenyi Biotec) were used for CD4^+^ T cell isolation. Anti-Cy7 and anti-Biotin MicroBeads were used for the CD11b^+^ dermal DC isolation *via* a MACS cell separation system.

Primary antibodies were detected with Alexa Fluor-labeled secondary antibodies (Invitrogen). Cell nuclei were stained with Hoechst 33258 dye (Invitrogen). NAK5 (anti-Dsg3 IgG1 mAb) was used to stain epidermal sheets.

For *in vitro* blocking assays, anti-mouse antibodies against I-A/I-E (M5/114.15.2), CD25 (PC61), CD80 (16-10A1), CD86 (GL-1), CD275 (HK5.3), PD-1 (29F.1A12 and RMP1-14), PD-L1 (10F.9G2), IL-2 (JES6-1A12), IL-6 (MP5-20F3) and IL-10 (JES5-16E3) from BioLegend, IL-15 (AIO.3) from eBioscience and TGF-beta (1D11) from R&D were used.

2.3. Epidermal Sheet and Cryosection Preparation {#s0025}
------------------------------------------------

Epidermal sheets were prepared as previously described ([@bb0135]). Briefly, mouse ears were divided into dorsal and ventral halves with forceps and incubated for 15 min at 37 °C on 3.8% ammonium thiocyanate (Wako Pure Chemical Industries) in phosphate buffer (pH 7.0). The epidermal sheets were manually detached from the dermis under a dissecting microscope (Olympus). Tissue samples for cryosections were embedded in O.C.T. compound (Tissue Tek) and frozen at − 80 °C.

2.4. Immunofluorescence Microscopy {#s0030}
----------------------------------

Staining of the epidermal sheets and cryosections was performed as previously described. Briefly, the epidermal sheets or cryosections were fixed in acetone at − 20 °C for 15 min and were rehydrated in PBS for at least 5 min (3 times). The samples were blocked with 3% dry milk (Morinaga) and 5% goat serum (Dako) in PBS for an hour at room temperature. The primary antibodies were incubated overnight at 4 °C and washed and detected with appropriate secondary antibodies. Nuclei were stained with Hoechst 33258 (Invitrogen). Image acquisition was performed with an Axio Observer.Z1 (Zeiss) and the AxioVision software (ver. 4.8), with a Leica confocal microscope (TCS-SP5, Leica) or with a Zeiss confocal microscope (LSM880, Zeiss) and the Zeiss Zen (v2.1) software. The levels of the images were linearly adjusted using Photoshop CS5 (Adobe) when necessary. 3D reconstruction images were built using sp5 software (Leica) and movies were processed using iMovie (Apple).

2.5. Cell Suspension Preparation {#s0035}
--------------------------------

Epidermal cell suspensions were prepared as previously described with slight modifications ([@bb0135]). The shaved mouse trunk skins were floated on RPMI 1640 medium containing 0.15% trypsin and 0.27 mM EDTA at 37 °C for 30 or 45 min. The epidermis was mechanically scraped off in 5% FCS-PBS and washed and filtered through cell strainers (BD Falcon). To obtain the dermal cell suspension, the dermis was minced with scissors or scalpels and incubated in RPMI 1640 medium containing 0.25 mg/ml of Liberase TL Research grade (Roche) and 200 U/ml of DNase I (Sigma) at 37 °C for 60 min. Skin-draining lymph nodes (brachial, axiliary, cervical and inguinal) and spleens were excised and disrupted through a cell strainer (BD Falcon) in 5% FCS-PBS to generate single cell suspensions.

2.6. Flow Cytometry {#s0040}
-------------------

Anti-mouse CD16/32 (clone 93, BioLegend) was routinely used to block Fcγ receptors. Non-viable cells were excluded with PI (Sigma-Aldrich), 7AAD (BioLegend) or LIVE/DEAD cell (Invitrogen). Intracellular staining for Foxp3 (FJK-16s) as well as for langerin (L31) was performed after cell surface staining using Foxp3 staining buffer (eBioscience). Intracellular staining for langerin was performed because there is no detectable cell-surface staining after trypsinization of epidermal cells (data not shown). Intracellular staining for pSTAT5 was performed by fixing cells with BD Phosflow™ Fix buffer I (BD Biosciences) followed by permeabilizing cells with BD Phosflow™ Perm Buffer III (BD Biosciences). Data acquisition was performed on a FACS Canto II (BD Biosciences) or LSR II (BD Biosciences) and analyzed using FlowJo (Tree star).

2.7. ELISA {#s0045}
----------

For cytokine analysis, cells harvested from epidermis, lymph nodes and spleens were incubated at a concentration of 2 × 10^6^/ml for 6 h in complete RPMI 1640 medium supplemented with PMA (5 ng/ml, Sigma-Aldrich) and ionomycin (500 ng/ml, Sigma-Aldrich). Quantification of cytokines in cell culture supernatants was performed using Mouse IL-17A or IFN-γ ELISA MAX™ Standard Sets (BioLegend) according to the manufacturer\'s instructions.

2.8. Preparation of Skin Dendritic Cells {#s0050}
----------------------------------------

LCs that migrated from skin explants were isolated as previously described ([@bb0135]). In short, mouse ears were divided into dorsal and ventral halves, cartilage was removed, and the ear halves were then floated on 40 ml of complete RPMI 1640 medium supplemented with Amphotericin B at 37 °C in 10-cm petri dishes. The cells that migrated into the culture medium were collected after 24 h and were stored at 4 °C. These cells were pooled with cells that were harvested after an additional 24 h of skin explant incubation in newly replaced culture medium. EpCAM^−^ CD11b^+^ dermal DCs were isolated from dermal cell suspensions using a MACS cell separation system (Miltenyi Biotec).

2.9. *In vitro* T Cell Proliferation Assay {#s0055}
------------------------------------------

To generate pure and naïve H1 cells, 2 × 10^6^ bone marrow cells from *Rag2*^−/−^ H1 mice were transferred into lethally irradiated (9.5 Gy) Dsg1-transgenic *Dsg3*^−/−^ mice. CD4^+^ T cells were isolated from spleen and lymph nodes of the bone marrow chimeric mice using a MACS cell separation system (Miltenyi Biotec). H1 or WT polyclonal CD4^+^ T cells (2 × 10^5^ CFSE-labeled) (Life Technologies) were co-cultured with 1 × 10^4^ LCs in 96-well round-bottom plates. The cells were harvested for analysis on day 3. For *in vitro* blocking assays, 10 μg/ml of anti-mouse monoclonal antibodies were added. 10 ng/ml of recombinant mouse IL-2 (R&D) in PBS was used for IL-2 treatment experiments.

2.10. Experimental Autoimmune Dermatitis {#s0060}
----------------------------------------

CD4^+^ T cells were isolated from spleens and lymph nodes of H1 mice *via* a MACS cell separation system (Miltenyi Biotec), and 5 × 10^6^ cells were injected intravenously into *Rag2*^−/−^ and Langerin-DTA *Rag2*^−/−^.

2.11. Statistical Analysis {#s0065}
--------------------------

Statistical analyses were performed with Student\'s *t*-test using Prism version 5 for MAC OS X (GraphPad Software), and *p* values ≤ 0.05 were regarded as significant.

2.12. Nanostring Analysis {#s0070}
-------------------------

Skin-explant LCs were treated with 10 ng/ml of rIL-2 for 8 h and RNA was subsequently extracted. Nanostring analysis was performed according to the manufacturer\'s instructions.

Raw data from the rIL-2 treated skin-explant LCs were uploaded to nSolver Nanostring software and processed with default quality control settings. Per sample transcript counts were normalized to the six positive controls in the nCounter panel and six housekeeping genes (*Gusb*, *Oaz1*, *Polr2a*, *Ppia*, *Rpl19*, *Tubb5*) and samples were subsequently partitioned by treatment group (WT or WT + rIL-2). Ratios for the comparison of treatment groups and associated *p*-values were generated by the nSolver software.

A heatmap was generated in nSolver using normalized expression values for the 19 genes that were significantly different (*p* \< 0.05) in both experiments.

A scatterplot for expression data was generated using group expression values exported from nSolver into Excel, where values were log-transformed and subsequently plotted in Prism. Genes were chosen for display out of the 561 total genes analyzed based on their statistical or biological significance.

2.13. Ingenuity Pathway Analysis {#s0075}
--------------------------------

Gene expression data from the nCounter Mouse Immunology Panel were analyzed using Ingenuity Pathway Analysis Version 01-07 (Qiagen). Uploaded ratios from nSolver software were converted to fold change values in IPA for core analysis and used to calculate a z-score and *p*-value corresponding to the prediction of up- or downregulation in Canonical Pathways and Diseases or Functions annotations in the IPA database. Canonical Pathways with significant (*p* \< 0.05) up- or downregulation in rIL-2-treated LCs were filtered by \| z-score \| \> 1 and assessed for biological relevance. Diseases and Functions were assessed based on their IPA-predicted activation state (\| z-score \| \> 2).

3. Results {#s0080}
==========

3.1. Langerhans Cells Take Up and Present Desmoglein 3 {#s0085}
------------------------------------------------------

To determine if LCs take up keratinocyte-associated autoantigens, we first examined epidermal sheets from wild-type mice and stained them for class II MHC (MHC II) and Dsg3. The conformation of the extracellular portion of Dsg3 relies on an optimal calcium concentration ([@bb0010]), which is unlikely to be retained after its internalization within LCs. Utilizing an anti-Dsg3 mAb that recognizes non-conformational epitopes in a calcium-independent manner ([@bb0085]), we detected punctate Dsg3 signals within LCs which were distinct from signals of cytoplasmic MHC II ([Fig. 1](#f0005){ref-type="fig"}A). To confirm that this observation represented Dsg3 uptake by LCs from keratinocytes, we generated transgenic mice that expressed a Dsg3-eGFP fusion protein driven by the keratin 5 promoter ([Fig. 1](#f0005){ref-type="fig"}B). Only epidermal keratinocytes express Dsg3-eGFP in the skin of these mice and the eGFP signal was detected in epidermal sheets and CD45^−^ MHC II^−^ keratinocytes *via* flow cytometry ([Fig. 1](#f0005){ref-type="fig"}C,D). Interestingly, we found that up to 5% of LCs were eGFP^+^ *via* flow cytometry analysis of epidermal cell suspensions, while eGFP signals were not found in dendritic epidermal T cells ([Fig. 1](#f0005){ref-type="fig"}E,F), indicating that a subset of LCs had taken up Dsg3-eGFP fusion protein within the epidermis. Similarly, Dsg3^+^ LCs were detected in WT mice by flow cytometry analysis *via* anti-Dsg3 antibody staining ([Fig. 1](#f0005){ref-type="fig"}F, right panel). Rare Langerin^−^ CD11b^+^ dermal DCs in Dsg3-eGFP mice also contained eGFP ([Fig. 1](#f0005){ref-type="fig"}G), thereby demonstrating that LCs were the predominant but not the sole APC subset that had access to keratinocyte-expressed Dsg3-eGFP fusion protein.Fig. 1LCs acquire Dsg3 from keratinocytes and activate Dsg3-specific T cells. (A) Dsg3 co-stained with MHC II in epidermal sheets. Bar = 10 μm. (B) Construct map for K5-Dsg3-eGFP mice generation. (C) eGFP visualization in epidermal sheets from K5-Dsg3-eGFP transgenic mice. Bar = 100 μm. (D) eGFP expression in CD45^−^ MHC II^−^ keratinocytes from K5-Dsg3-eGFP and WT mice *via* flow cytometry. (E) eGFP detection in CD45^+^ MHC II^hi^ EpCAM^+^ LCs and CD45^hi^ CD3ε^hi^ MHCII^−^ EpCAM^−^ dendritic epidermal T cells (DETC). (F) Quantification of eGFP^+^ LCs and DETCs in WT and K5-Dsg3-eGFP mice (left panel) and quantification of Dsg3^+^ LCs and DETCs in WT mice after staining with anti-Dsg3 (NAK5) and detection by flow cytometry (right panel). (G) Detection of eGFP^+^ CD45^+^ MHC II^+^ CD11b^+^ EpCAM^−^ dermal cells from K5-Dsg3-eGFP mice. (H) CFSE-dilution assay for H1^*Rag*^ cells co-cultured with LCs in the presence of an anti-MHC II blocking antibody or an isotype control. As in (H) H1^*Rag*^ cells co-cultured with (I) skin-explant LCs from WT (LC^WT^) or *Dsg3* −/− (LC^Dsg3 −/−^) mice and (J) skin-explant LC^WT^ or CD11b^+^ dermal DCs from WT mice. Data are representative of three independent experiments (n = 3). *p* values: \*\<0.05, \*\*\<0.01, \*\*\*\*\<0.0001.Fig. 1

3.2. LCs Present Dsg3 in the Context of MHC Class II {#s0090}
----------------------------------------------------

To functionally evaluate the immunological consequences of Dsg3 uptake by LCs, we collected LCs from skin explants of unmanipulated WT mice (LC^WT^) to be used as APCs. A subset of them would be expected to have taken up Dsg3 from surrounding keratinocytes ([Fig. 1](#f0005){ref-type="fig"}A,E,F). To generate responder T cells, *Rag2*^−/−^ mice were crossed to TCR (Vβ~6~) transgenic mice in which CD4^+^ T cells express a Dsg3-specific TCR (H1 cells) ([@bb0195]). Bone marrow from these mice was transferred into lethally irradiated *Dsg3*^−/−^ mice ([@bb0045]). This procedure enabled the development of Dsg3-reactive T cells in a Dsg3-deficient environment and resulted in high ratios of naïve, Vβ~6~-expressing H1 cells (hereafter referred to as H1^*Rag*^ cells) in the recipient mice (data not shown) ([@bb0195]).

When LC^WT^ were co-cultured with carboxyfluorescein succinimidyl ester (CFSE)-labeled H1^*Rag*^ cells, H1^*Rag*^ cells underwent robust proliferation, which was completely blocked by antibodies against MHC II ([Fig. 1](#f0005){ref-type="fig"}H). LCs collected from the skin explants of *Dsg3*^−/−^ mice (LC^Dsg3 −/−^) failed to activate H1 cells ([Fig. 1](#f0005){ref-type="fig"}I), indicating that H1^*Rag*^ cell proliferation occurred in a Dsg3-specific manner. These data demonstrated that the LCs acquired Dsg3 from surrounding keratinocytes and presented it in the context of MHC II to H1^*Rag*^ cells. In contrast to LCs, EpCAM^−^ CD11b^+^ dermal DCs did not activate H1^*Rag*^ cells ([Fig. 1](#f0005){ref-type="fig"}J). This can be explained by the small number of dermal DCs that had acquired Dsg3 and in aggregate demonstrate that LCs were the predominant APC that took up and presented Dsg3.

3.3. Langerin Is Required for the Uptake of Dsg3 {#s0095}
------------------------------------------------

Langerin binds carbohydrate residues ([@bb0205]). We hypothesized that the uptake of Dsg3 by LCs, a highly glycosylated protein, may be mediated by langerin. When we co-stained langerin and Dsg3 in epidermal sheets prepared from WT mice, we observed that the punctate Dsg3 signal in LC cytoplasm co-localized with langerin ([Fig. 2](#f0010){ref-type="fig"}A, [Supplementary Movie 1](#ec0010){ref-type="supplementary-material"}). Based on the predominantly cytoplasmic localization of MHC II, these LCs exhibited an immature phenotype (data not shown). To explore the role of langerin in immune responses, we utilized mice in which the extracellular domain of the langerin gene is replaced by the simian diphtheria toxin receptor (DTR) (Langerin-DTR mice) ([@bb0015]). Mice homozygous for the *langerin-*DTR allele (Langerin^DTR/DTR^) lack functional langerin. Indeed, staining of epidermal sheets from Langerin^DTR/DTR^ mice for MHC II and langerin revealed that LCs existed in a normal distribution within the epidermis but displayed an absence of langerin expression ([Fig. 2](#f0010){ref-type="fig"}B). Apart from their lack of langerin, LCs (LC^DTR/DTR^) from Langerin^DTR/DTR^ mice were phenotypically indistinguishable from LC^WT^ with regard to MHC II, CD80 and CD86 expression (data not shown).

We utilized skin-explant LC^WT^ and LC^DTR/DTR^ as APCs in an *in vitro* proliferation assay with CFSE-labeled H1^*Rag*^ cells as responder T cells. We also phenotypically evaluated H1 cells that had proliferated into T~reg~ and effector T cells (T~eff~ cells). LC^WT^ induced the proliferation of both T cell subsets ([Fig. 2](#f0010){ref-type="fig"}C). Notably, T~reg~ cells were generated despite the absence of *Rag2*, a condition that does not favor T~reg~ cell generation ([@bb0185]).Fig. 2Langerin is required for Dsg3 uptake. (A) Confocal microscopy of epidermal sheets co-stained with anti-Dsg3 (NAK5) and anti-langerin mAbs. Lower panels show high magnification of the outlined area in the upper panels. Bars = 20 μm (upper) and 10 μm (lower). (B) Immunofluorescence microscopy of epidermal sheets from Langerin^DTR/WT^ or Langerin^DTR/DTR^ mice co-stained with anti-MHC II and anti-langerin mAbs. (C) CFSE-labeled H1 cells co-cultured with skin-explant LCs from WT (LC^WT^), Dsg3 −/− (LC^Dsg3 −/−^), Langerin^DTR/DTR^ (LC^DTR/DTR^) or Langerin^DTR/WT^ (LC^DTR/WT^) mice. (D) Y-axis, percent divided, represents the frequency of cells among the original input population of CD4^+^ Vβ5^+^ T cells that have undergone division. *p* values: \*\*\*\*\<0.0001.Fig. 2

In contrast to LC^WT^, LC^DTR/DTR^ were markedly impaired in their ability to activate H1^*Rag*^ T~reg~ and T~eff~ cells ([Fig. 2](#f0010){ref-type="fig"}C,D), indicating that langerin mediated Dsg3 uptake prior to antigen presentation. LCs that were heterozygous for the langerin-DTR allele, LC^DTR/WT^, were modestly impaired in activating H1^*Rag*^ cells ([Fig. 2](#f0010){ref-type="fig"}D), likely reflecting decreased Dsg3 acquisition and presentation of fewer Dsg3 peptide-MHC II complexes to T cells. These results demonstrated a critical role for langerin during the acquisition of a keratinocyte-derived autoantigen.

3.4. LCs Are Required for T~reg~ Cell Expansion *In Vivo* {#s0100}
---------------------------------------------------------

Because skin-explant LC^WT^ expanded both T~reg~ and T~eff~ H1^*Rag*^ cells *in vitro* ([Fig. 2](#f0010){ref-type="fig"}C), we sought to confirm the role of LCs in EAD, a CD4^+^ T cell-mediated autoimmune response against Dsg3 ([@bb0195]). In this model, when H1 cells are adoptively transferred into *Rag2*^−/−^ mice, they readily infiltrate the skin and elicit IFN-γ-dependent responses directed against keratinocytes (which express Dsg3), causing apoptosis and obscuring the dermo-epidermal junction ([@bb0195]).

We crossed Langerin-DTA (diphtheria toxin fragment A) mice ([@bb0065]), which constitutively lack LCs, to the *Rag2*^−/−^ background and adoptively transferred CD4^+^ T cells that were collected from *Rag2*-sufficient H1 mice (30--40% H1 cells). The utilization of H1 cells in the *Rag2*-sufficient background facilitates T~reg~ cell analysis ([@bb0185]). EAD developed in Langerin-DTA *Rag2*^−/−^ mice ([Fig. 3](#f0015){ref-type="fig"}A), consistent with a previous demonstration of autoimmune T cell activation in the absence of DCs ([@bb0200]). Interestingly, Langerin-DTA *Rag2*^−/−^ mice exhibited an aggravated skin phenotype with significantly elevated clinical scores ([Fig. 3](#f0015){ref-type="fig"}A). Histological analysis revealed a more prominent interface dermatitis in Langerin-DTA *Rag2*^−/−^ mice that was accompanied by an increased number of CD4^+^ Vβ~6~^+^ (Dsg3-specific) cells in the epidermis ([Fig. 3](#f0015){ref-type="fig"}B,C).Fig. 3The loss of LCs leads to exacerbated autoimmunity. H1 T cells were adoptively transferred into *Rag2*^−/−^ mice to generate EAD. (A) Phenotype (3 weeks post transfer) and clinical scores of EAD in mice that have (*Rag2*^−/−^) or lack (Langerin-DTA *Rag2*^−/−^) LCs. *p* = 0.0215. (B) H&E (upper panels) and frozen sections stained for CD4 (lower panels) from lesional skin of EAD in indicated mice. (C) Quantification of CD45^+^ CD3^+^ CD4^+^ Vβ~6~^+^ cells in the epidermis *via* flow cytometry. (D) Supernatants of *in vitro* stimulated (PMA/ionomycin) epidermal cell suspensions were analyzed for IFN-γ or IL-17 concentration *via* ELISA. (E) Quantification of Vβ~6~^+^ T~reg~ cells in skin-draining lymph nodes and spleen in indicated mice *via* flow cytometry.  *p* values: \*\<0.05, \*\*\<0.01.Fig. 3

*Re*-stimulation of CD4^+^ T cells from lesional epidermis *in vitro* revealed an increased production of IL-17 as well as a trend toward increased IFN-γ ([Fig. 3](#f0015){ref-type="fig"}D). Flow cytometry analysis of the skin-draining lymph nodes revealed a decreased expansion of T~reg~ cells in mice that lacked LCs ([Fig. 3](#f0015){ref-type="fig"}E). In aggregate, although LCs activated both T~eff~ and T~reg~ H1 cells *in vitro*, the lack of LCs led to impaired expansion of T~reg~ cells and exacerbated inflammation *in vivo*, highlighting their role in suppressing autoimmunity.

3.5. LCs Preferentially Expand Polyclonal T~reg~ Cells {#s0105}
------------------------------------------------------

Human LCs are capable of expanding polyclonal T~reg~ cells *in vitro* in the absence of exogenous antigens or stimulation ([@bb0165]). To explore the mechanism by which skin explant LCs expand T~reg~ cells, we utilized CSFE-labeled syngeneic WT CD4^+^ T cells as responder cells rather than H1^*Rag*^ cells because the activation of T~eff~ cells and cytokines that they produce may have secondary effects on T~reg~ cell expansion.

Consistent with the human setting, a significant portion of T~reg~ cells, but not T~eff~ cells, underwent proliferation ([Fig. 4](#f0020){ref-type="fig"}A), demonstrating that LCs preferentially expanded T~reg~ cells in the absence of autoimmune T cells. The T~reg~ cells that proliferated in this experiment may be specific for various epidermal self-antigens that were acquired by LCs.Fig. 4LCs induce the expansion of polyclonal T~reg~ cells (A) CFSE-dilution assay utilizing polyclonal CD4^+^ T cells that were isolated from syngeneic WT mice, co-cultured with skin-explant WT LCs. Dot plots show the gating strategy for CD4^+^ T cells after co-culture. Histograms show FoxP3^+^ or FoxP3^−^ CD4^+^ T cells. (B) Real-time PCR analysis for indicated cytokine mRNA expressed by skin-explant LCs (Explant LCs), LCs (Fresh LCs), keratinocytes and dendritic epidermal T cells (DETCs) that were FACS sorted from freshly prepared epidermal cell suspensions. (C - F) CFSE-dilution assay as in (A) with antibodies or isotypes added to the co-culture as indicated. The Y-axis, percent divided, represents the frequency of CD4^+^ FoxP3^+^ T cells among original input population that have undergone division. (G) Flow cytometry analysis for cell-surface markers on T~reg~ cells expanded by LCs *in vitro*, stained with antibodies against indicated molecules (red) or isotypes (gray). *p* values: \*\<0.05, \*\*\<0.01, \*\*\*\*\<0.0001.Fig. 4

LCs in epidermal cell suspension as well as those from skin explants expressed a variety of molecules that play major roles in immune regulation, including MHC II, CD80, CD86 and PD-L1 (data not shown) as well as cytokines IL-6, 10, 15, and TGF-β1 ([Fig. 4](#f0020){ref-type="fig"}B). We added neutralizing antibodies against these and other molecules that are involved T~reg~ cell induction ([@bb0020], [@bb0035]), and found that only anti-MHC II and anti-IL-2 antibodies had notable effects on T~reg~ cell expansion, with modest effects of IL-6 blockage ([Fig. 4](#f0020){ref-type="fig"}C,D,E). Blockage of IL-2 receptor alpha (CD25) had a similar effect than IL-2 neutralization ([Fig. 4](#f0020){ref-type="fig"}F).

The importance of TGF-β1 for induced T~reg~ cells is well-established ([@bb0125]). The observation that a blocking antibody against TGF-β1 had no effect on LC-mediated T~reg~ cell expansion ([Fig. 4](#f0020){ref-type="fig"}E) was consistent with the down-regulation of *Tgfb1* expression by skin-explant LCs, as compared with LCs sorted from freshly prepared epidermal cell suspensions ([Fig. 4](#f0020){ref-type="fig"}B). Furthermore, thymus-derived T~reg~ cell markers Helios and Neuropilin-1 were expressed by LC-expanded T~reg~ cells ([Fig. 4](#f0020){ref-type="fig"}G). These data suggested that LCs mediate the expansion of naturally-occurring T~reg~ cells, rather than the expansion of induced T~reg~ cells. Thus, LCs expand T~reg~ cells that are likely to be naturally-occuring, *via* a mechanism that involves the IL-2-IL-2 receptor axis.

3.6. IL-2 Receptor Signaling in LCs {#s0110}
-----------------------------------

The effect of IL-2 and CD25 blockage on T~reg~ cells could be explained by direct effects on T cells. Interestingly, upon emigration skin-explant LCs highly upregulated CD25 (IL2Rα), consistent with previous reports ([@bb0120], [@bb0180]), and to a lesser extent IL-2Rβ and IL-2Rγ chains ([Fig. 5](#f0025){ref-type="fig"}A), suggesting that IL-2 might directly affect LCs.Fig. 5IL-2 signaling occurs in LCs and is required for optimal LC-mediated T~reg~ cell expansion (A) Expression of the IL-2 receptor complex by LCs from indicated sources. (B) Flow cytometry analysis for pSTAT5 in LCs from freshly prepared epidermal cell suspensions or lymph nodes from WT or CD25^−/−^ mice. (C) Grouped expression values for rIL-2-treated skin explant LCs (WT + rIL-2) were plotted against vehicle-treated LCs (WT + vehicle) for all 561 nCounter Mouse Immunology Panel (Nanostring) genes. (D) Differential gene expression between rIL-2- and vehicle-treated LCs was significant (*p* \< 0.05) for 19 genes in the Nanostring analysis. (E) Canonical IPA pathways with significant up- or downregulation in rIL-2-treated LCs. (F) CFSE-labeled syngeneic WT or CD25^−/−^ CD4^+^ T cells were co-cultured with WT or CD25^−/−^ LCs. (G) Quantification of the percentage of CD4^+^ FoxP3^+^ T cells from (F). The Y-axis, percent divided, represents the frequency of CD4^+^ FoxP3^+^ T cells among original input population that have undergone division. Data are representative of 3 independent experiments. *p* values: \*\<0.05, \*\*\<0.01, \*\*\*\*\<0.0001.Fig. 5

Signal transducer and activator of transcription 5 (STAT5) undergoes phosphorylation (pSTAT5) upon engagement of IL-2 with the IL-2 receptor complex ([@bb0140]). We therefore stained for pSTAT5 and detected it in LCs from both the epidermis and lymph nodes of WT mice. Furthermore, pSTAT5 levels were decreased in LCs from *CD25*^*−/−*^ mice ([Fig. 5](#f0025){ref-type="fig"}B), indicating that IL-2 signaling takes place in LCs.

To further characterize the effect of IL-2 on LCs, skin-explant LCs obtained from WT mice ([Fig. S1](#f0035){ref-type="graphic"}A,B) were exposed to recombinant IL-2 (rIL-2) *in vitro* for 8 h. RNA was extracted and transcripts for 561 immunology-related genes were quantified *via* Nanostring analysis. rIL-2 induced gene expression changes in LCs ([Fig. 5](#f0025){ref-type="fig"}C). Highly significant changes included decreased expression of *Ciita*, a regulator of MHC II, and increased *Tgfb1* and *Smad3* expression ([Fig. 5](#f0025){ref-type="fig"}D), both of which are associated with TGF-β signaling and LC migration ([@bb0130]). There was a trend for upregulated *Il2rg* expression as well as statistically significant upregulation of *Il2rb* in response to rIL-2 ([Fig. 5](#f0025){ref-type="fig"}C,D).

To predict the biological significance of rIL-2-induced overall gene expression changes in LCs, we performed Ingenuity Pathways Analysis. Whereas the mitogen-activated protein kinases (MAPK) signaling pathway has been reported to be activated in response to ultraviolet irradiation in LCs ([@bb0215]), rIL-2 exposed LCs exhibited downregulation of these pathways ([Fig. 5](#f0025){ref-type="fig"}E). Among upregulated pathways were those that related to cell motility and migration, as well as PI3K/AKT and p14/p19ARF pathways, both of which have been demonstrated to be required for LC homeostasis ([@bb0090], [@bb0170]). Significant decreases in disease-associated pathways that reflect the activation of APCs were also detected ([Table S1](#ec0005){ref-type="supplementary-material"}). Taken together, rIL-2 has effects on biological pathways that are known to be relevant in LC physiology, suggesting that IL-2 signaling in LCs evokes a less activated but motile phenotype that may represent homeostatic migration of LCs that carry autoantigens ([@bb0050]) and is consistent with a previous study reporting IL-2-mediated increased DC motility in rats ([@bb0110]).

In contrast to human *in vitro* derived DCs that produce IL-2 to activate T cells ([@bb0230]), LCs did not express *Il2* ([Fig. 4](#f0020){ref-type="fig"}B). We therefore hypothesized that LCs may acquire IL-2 from T~eff~ cells, a major source of IL-2. Indeed, immunofluorescence analysis of cytospin preparation of LCs and syngeneic WT CD4^+^ T cells that were co-cultured for 4 days revealed that LCs were in close proximity to IL-2^+^ FoxP3^−^ T cells, and that LCs had acquired IL-2 protein on their cell surfaces ([Fig. S2](#f0040){ref-type="graphic"}A). Similarly, IL-2-bearing LCs were observed near IL-2^+^ cells in the T cell zone in skin draining lymph nodes ([Fig. S2](#f0040){ref-type="graphic"}B). These data suggested that LCs acquire IL-2 from IL-2-producing T cells nearby. Given that dendritic epidermal T cells express *Il2* ([Fig. 4](#f0020){ref-type="fig"}B) and that pSTAT5 is decreased in epidermal LCs of CD25^−/−^ mice ([Fig. 5](#f0025){ref-type="fig"}B), dendritic epidermal T cells may represent the source of IL-2 for LCs that reside within the epidermis.

3.7. IL-2-Mediated LC Conditioning Is Required for T~reg~ Cell Expansion {#s0115}
------------------------------------------------------------------------

Finally, to determine the consequence of impaired IL-2 signaling in LCs during T~reg~ cell proliferation, we co-cultured WT syngeneic T cells with skin explant LC^WT^ and LCs from CD25^−/−^ mice (LC^CD25 −/−^) and found that LC^CD25 −/−^ were impaired in their capability to induce the proliferation of CD25^+^ FoxP3^+^ T~reg~ cells ([Fig. 5](#f0025){ref-type="fig"}F,G). To eliminate the effect of CD25 expressed on T cells, we co-cultured LC^WT^ or LC^CD25 −/−^ with CD25^−/−^ CD4^+^ T cells. This experiment is valid because FoxP3^+^ Treg cells are able to develop in CD25^−/−^ mice ([@bb0035]). Indeed, CD25^−/−^ CD4^+^ FoxP3^+^ T cells co-cultured with LC^WT^ underwent robust proliferation, likely reflecting their hyperactivated state *in vivo* ([@bb0220]). However, consistent with the results obtained with WT CD4^+^ T~reg~ cells, co-culture with LC^CD25 −/−^ led to a decreased proliferation of CD25^−/−^ CD4^+^ FoxP3^+^ T~reg~ cells ([Fig. 5](#f0025){ref-type="fig"}F,G). These data collectively demonstrate that CD25 on LCs was required for optimal T~reg~ cell expansion and that the IL-2-IL-2 receptor axis in LCs conditioned them to expand T~reg~ cells.

4. Discussion {#s0120}
=============

Pemphigus vulgaris is an autoantibody-mediated blistering skin disease, which can be debilitating and potentially life-threatening if not properly treated ([@bb0175]). Although IgG-mediated inhibition of Dsg3 function is the major mechanism that leads to the loss of keratinocyte adhesion and blister formation, autoreactive T cells participate upstream in the immune response to help B cells to produce autoantibodies ([@bb0190]), and further upstream, it is likely that APCs acquire and present autoantigens to activate autoreactive T cells. Better understanding of mechanisms by which APCs take up an epidermal autoantigen such as Dsg3, and better characterization of subsequent immune responses would provide a foundation for the development of novel therapeutic strategies against not only pemphigus vulgaris, but also other autoimmune blistering diseases that target epidermal antigens, such as bullous pemphigoid, epidermal bullosa acquisita, and perhaps other T cell-mediated diseases such as lichen planus and erythema multiforme, in which T cells directly mediate the cell death of keratinocytes ([@bb0040]). In this work, we asked whether LCs, given their proximity to keratinocyte-associated autoantigens, are the major APC to regulate immune responses against keratinocyte-expressed Dsg3.

In previous work, functional analyses of LCs had utilized infectious agents or haptens, and the conclusion of experiments that explored the tolerogenic aspects of LCs had been somewhat variable ([@bb0070], [@bb0075]). The nature of antigens, how and where they are captured, as well as the location and extent of inflammation may influence experimental outcomes. The experimental systems utilized herein were unique in that we did not utilize any exogenous antigens, neoantigens or adjuvants, which may alter the homeostatic function of LCs. Dsg3 is expressed exclusively by epidermal keratinocytes in the skin. Owing to this, no manipulations were required to observe LCs\' immune responses toward the antigen, ensuring that LCs captured Dsg3 in the absence of external cues, and importantly, at physiological doses.

The discovery of langerin reoriented the LC field, allowing for the identification of migrated LCs and the generation of *in vivo* depletion models ([@bb0015], [@bb0065], [@bb0105], [@bb0205]). However, despite its demonstration as an endocytic receptor *in vitro* ([@bb0205]), langerin-deficient mice failed to exhibit any obvious phenotypes ([@bb0100]). Furthermore, although langerin functions as a scavenging receptor against HIV ([@bb0225]), its roles in immune responses had remained incompletely characterized. The co-localization of langerin with non-conformational Dsg3 epitopes within LCs prompted us to address the role of langerin during self-antigen uptake. This hypothesis, that the C-type lectin langerin could bind Dsg3, was reasonable because Dsg3 is highly glycosylated ([@bb0005]). Because langerin is essential for the formation of Birbeck granules ([@bb0205]) and Birbeck granules are reportedly involved in the routing of antigen for antigen processing ([@bb0210]), more work is needed to unequivocally show that langerin mediates the uptake of, rather than the proper routing of, acquired antigens.

We observed an upregulation of the IL-2 receptor complex on skin-explant LCs. It has long been known that mature Langerhans cells express CD25 (IL2Rα) ([@bb0120], [@bb0180]), however, the functional role of IL2Rα for LCs has remained largely unknown. Our data show that IL-2 signaling actually takes place within LCs and conditions them to optimally induce T~reg~ cell expansion. *In vitro*-derived human myeloid DCs produce IL-2. Because blockage of CD25 on DCs impaired their ability to activate T cells, it was suggested that DCs present IL-2 in-trans *via* CD25 to activate T cells ([@bb0230]). However, LCs did not express IL-2 mRNA before or after emigration from the skin. Although it remains to be investigated where this event occurs, gene expression analyses of LCs and data from *in vitro* co-culture experiments suggested that LCs and T~reg~ cells may acquire biologically active IL-2 from nearby non-T~reg~ cells in the epidermis and/or the lymph nodes. While IL-2 conditions LCs to induce T~reg~ cell expansion, T~reg~ cells also require the cytokine for proliferation. Furthermore, T~reg~ cells additionally require antigen presentation by LCs, collectively forming a unique triangular relationship ([Fig. 6](#f0030){ref-type="fig"}). IL-2 signaling has not been previously demonstrated to take place in APCs, and it would be of interest to determine if this phenomenon can be extended to other APC subsets.Fig. 6Triangular cell interaction supports T~reg~ proliferation. Langerhans cells take up Desmoglein-3 *via* langerin and display it through MHC-II molecules to induce T~reg~ proliferation. In addition, IL-2 produced by non-T~reg~ cells is required for both conditioning of LC function and subsequent T~reg~ cell expansion.Fig. 6

Naive T~reg~ cells are thought to circulate until they are activated by DCs in the lymph node ([@bb0125]). Some activated T~reg~ cells can become memory T~reg~ cells, whose presence has been shown in both mouse and human skin ([@bb0155], [@bb0160]). T~reg~ cells have also been found in human epidermis ([@bb0165]) where they co-localized with LCs. It was postulated that the direct association of LCs and T~reg~ cells in skin may be involved in memory responses. It is therefore possible that LCs regulate various aspects of the T~reg~ cell life cycle. Although our study in mice cannot yet be directly translated to human diseases, it is reasonable to hypothesize that LC-T~reg~ cell interactions are also relevant in various autoimmune and inflammatory skin diseases, thereby representing an attractive therapeutic target.

In conclusion, we have demonstrated that LCs take up the epidermal antigen Dsg3 *via* langerin and that direct IL-2-mediated signaling conditions them to optimally induce the expansion of T~reg~ cells. Although LCs activated both T~eff~ and T~reg~ cells in the autoimmune setting, the loss of LCs *in vivo* led to exacerbated skin inflammation. Taken together, the finding that LCs preferentially induced the expansion of polyclonal T~reg~ cells suggests that LCs suppress autoimmunity *via* T~reg~ cell expansion in the steady state. This observation is consistent with a previous report, in which epicutaneously administered Dsg3 induced skin inflammation in MRL-lpr mice, a model of systemic autoimmunity ([@bb0095]). Further work should be conducted to determine the functional role of the IL-2 pathway in LCs *in vivo* and the mechanism by which IL-2-conditioned LCs induce the expansion of T~reg~ cells. Considering previous studies that have demonstrated LCs\' roles in protective immunity ([@bb0060], [@bb0145]), LCs are likely to be versatile and context-dependent in their function ([@bb0025]). Exploring environmental cues that govern LCs\' immunological polarity should enable new strategies to control skin immunity and to achieve tolerogenic responses in autoimmune skin diseases.

The following are the supplementary data related to this article.Fig. S1Purity of skin-explant LCs. (A) Gating strategy for skin-explant LCs from WT mice that were subsequently exposed to recombinant IL-2. (B) mRNA levels of LC-derived genes (*Cd74*, *Cd80*, *Cd86*) and T cell-derived *Cd3e* as determined by Nanostring analysis performed in [Fig. 5](#f0025){ref-type="fig"}C--E.Fig. S1Fig. S2LCs acquire IL-2 from neighboring IL-2-producing, non-T~reg~ cells. (A) WT CD4^+^ T cells and WT LCs were co-cultured for 3 days followed by preparation of cytospins and staining for IL-2 and langerin. Bar = 10 μm. (B) Frozen sections from inguinal lymph nodes of WT C57/BL6 mice were stained for CD25, IL-2, langerin and FoxP3. Bar = 10 μm. All data are representative of two independent experiments (n = 3).Fig. S2Table S1Functional predictions for transcriptional changes in rIL-2-treated LCs *via* Ingenuity Pathway Analysis.Table S1Supplementary Movie 1Co-localization of langerin and Dsg3 signals in epidermal LCs.Supplementary Movie 1
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